BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI-enabled drug discovery company, announces that AstraZeneca has selected an additional novel target for idiopathic pulmonary fibrosis (IPF) for its drug development portfolio, resulting in a milestone payment to BenevolentAI.
This is the third novel target from the collaboration that has been identified using the Benevolent Platform
The Benevolent Platform
Professor Maria Belvisi, SVP and Head of Research and Early Development, Respiratory and Immunology at AstraZeneca commented: “IPF is a devastating disease with median survival of around 3 years and there is a serious need for better treatment options. At AstraZeneca, we are continuously striving to improve our R&D productivity in order to quickly bring potentially innovative treatments to complex diseases such as IPF. Our partnership with BenevolentAI furthers our commitment and we are proud to deliver a second novel target for IPF to our portfolio.”
Dr. Anne Phelan, Chief Scientific Officer at BenevolentAI commented: “Target identification is an essential first step in the drug discovery pipeline, and where we believe the Benevolent Platform
Got a Questions?
Find us on Socials or Contact us and we’ll get back to you as soon as possible.